


Tufts Health Care Institute
Program on
Opioid Risk Management

Mission

To address challenges in the development and utilization of opioid analgesics, by engaging a multidisciplinary group of stakeholders focused on optimizing the benefits of opioids for pain management, and minimizing their risks, including abuse and diversion.



Program Structure

- Meetings in neutral, educational environment for free exchange of information and ideas
- Non-for-profit organizational structure; cost neutral financial model; multi-pharma support
- Meetings organized informally through networking, literature, organizational requests
- Emphasis on engaging medical and scientific communities through publications
- Emerging policy and advocacy agenda

Program Accomplishments

Foundations of Opioid Risk Management

Nathaniel P. Katz, MD, MS, † Edgar H. Adams, ScD, ‡ James C. Benneyan, PhD, §
Howard G. Birnbaum, PhD, ¶ Simon H. Budman, PhD, ¶¶ Ronald W. Buzzco, RPh, **
Daniel B. Carr, MD, * Theodore J. Cicero, PhD, † † Douglas Gourlay, MD, ‡ ‡
James A. Inciardi, PhD, §§ David E. Joranson, MSSW, || James Kesslick, MS, ¶ ¶ and
Stephen D. Lande, PhD, ¶ ¶ ¶*



Program Accomplishments

Challenges in the Development of Prescription Opioid Abuse-Deterrent Formulations

Authors:

Nathaniel P. Katz, MD, MS, Tufts University School of Medicine, Boston, MA
Edgar H. Adams, ScD, Covance, Princeton, NJ
Howard Chilcoat, ScD, GlaxoSmithKline, Research Triangle Park, NC
Robert D. Colucci, PharmD, Colucci & Associates LLC, Newtown, CT
Sandra D. Comer, PhD, Columbia University College of Physicians & Surgeons, New York, NY
Philip Goliber, PhD, Penwest Pharmaceuticals Co., Danbury, CT
Charles Grudzinskas, PhD, NDA Partners LLC, Annapolis, MD
Donald Jasinski, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD
Stephen D. Lande, PhD, Interactive Forums, Inc., Bala Cynwyd, PA
Steven D. Passik, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Sidney H. Schnoll, MD, PhD, Pinney Associates, Bethesda, MD
Edward Sellers, MD, PhD, Ventana Clinical Research Corporation, and University of Toronto, Toronto, Canada
Debra Travers, MT (ASCP), Endo Pharmaceuticals, Chadds Ford, PA
Roger Weiss, MD, Harvard Medical School, Boston, MA

*IMPLICIT
CLAIMS*

*EXPLICIT
CLAIMS*




Program Accomplishments

\$ Fundraising \$




Program Accomplishments

“Best Practices in Opioid Risk Management”




Program Accomplishments

“FDA Guidance on Developing Abuse-Deterrent Opioid Formulations”



CITIZEN'S
PETITION
SCIENTIFIC
BACKGROUND
DOCUMENT



Program Accomplishments

Responding to Signals of Prescription Opioid Abuse

Signal Prioritization
Signal Verification: Ultra-rapid Assessment
Cost-effective Interventions
Evaluation of Interventions

